Novartis International AG /
Novartis announces secukinumab (AIN457) demonstrated superiority to Enbrel® in
head-to-head Phase III psoriasis study
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* FIXTURE trial of m ...
↧